AR044586A1 - Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion - Google Patents

Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion

Info

Publication number
AR044586A1
AR044586A1 ARP040101890A ARP040101890A AR044586A1 AR 044586 A1 AR044586 A1 AR 044586A1 AR P040101890 A ARP040101890 A AR P040101890A AR P040101890 A ARP040101890 A AR P040101890A AR 044586 A1 AR044586 A1 AR 044586A1
Authority
AR
Argentina
Prior art keywords
group
independently selected
substituted
formula
alkyl
Prior art date
Application number
ARP040101890A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0306719A external-priority patent/FR2855825B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR044586A1 publication Critical patent/AR044586A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Composiciones que los contienen, y su utilización como medicamentos, en particular en oncología. Reivindicación 1: Productos que responden a la fórmula general (1), en la cual: A es N ó C; L-G-R1 se elige entre un resto de grupo de fórmula (2); X e Y se eligen independientemente entre CR3, N, NR3, O ó S; E es CR4, N, NR4 ó S; R1, R2 se seleccionan independientemente del grupo constituido por arilo, heteroarilo, arilo sustituido, heteroarilo sustituido; L se selecciona del grupo constituido por C=O, C=S, C=N(R7); R3, R4 se seleccionan independientemente del grupo constituido por H, alquilo, cicloalquilo, cicloalquileno, heterociclilo, O-R7, SR7, SO-R7, SO2-(R7), N(R7)(R8), halógeno, arilo, heteroarilo, cicloalquilo sustituido, arilo sustituido, heteroarilo sustituido; R5, R6 se seleccionan independientemente del grupo constituido por H, alquilo (C1-3); R7, R8 se seleccionan independientemente del grupo constituido por H, alquilo (C1-3), alquilo (C1-3) sustituido; en forma racémica, enriquecida en un enantiómero, enriquecida en un diastereoisómero, sus tautómeros, sus profármacos y sus sales farmacéuticamente aceptables, con la condición de que el producto de fórmula (1) no sea uno de los compuestos siguientes: la fórmula (3); (copiar tabla); o un resto de grupo de fórmula (4), con n = 0, 1 ó 2 y R2 = fenilo.
ARP040101890A 2003-06-04 2004-06-02 Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion AR044586A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0306719A FR2855825B1 (fr) 2003-06-04 2003-06-04 Produits aryl-heteroaromatiques, compositions les contenant et utilisation
FR0404889 2004-05-06

Publications (1)

Publication Number Publication Date
AR044586A1 true AR044586A1 (es) 2005-09-21

Family

ID=33512659

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101890A AR044586A1 (es) 2003-06-04 2004-06-02 Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion

Country Status (17)

Country Link
US (1) US20050014765A1 (es)
EP (1) EP1641765A1 (es)
JP (1) JP4805813B2 (es)
KR (1) KR20060006850A (es)
AR (1) AR044586A1 (es)
AU (1) AU2004245269A1 (es)
BR (1) BRPI0411001A (es)
CA (1) CA2528093A1 (es)
CL (1) CL2004001359A1 (es)
HK (1) HK1093339A1 (es)
IL (1) IL172222A0 (es)
MX (1) MXPA05012929A (es)
PA (1) PA8604401A1 (es)
PE (1) PE20050226A1 (es)
TW (1) TW200510344A (es)
UY (1) UY28350A1 (es)
WO (1) WO2004108685A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
CA2580845A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CN101084207A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
EP2269610A3 (en) * 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP5080256B2 (ja) * 2004-09-20 2012-11-21 ゼノン・ファーマシューティカルズ・インコーポレイテッド 二環式複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼ（ＳＣＤ）のインヒビターとしてのそれらの使用
MX2007003327A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
BRPI0515499A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de piridina para a inibição de estearoil-coa-desaturase humana
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
BRPI0515488A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
JP2009513563A (ja) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
TW200800946A (en) * 2005-08-15 2008-01-01 Astrazeneca Ab Substituted piperazines as metabotropic glutamate receptor antagonists
US20090281097A1 (en) * 2006-04-14 2009-11-12 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
DE102006027229A1 (de) * 2006-06-09 2007-12-20 Grünenthal GmbH 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US8148367B2 (en) * 2007-01-12 2012-04-03 Takeda Pharmaceutical Company Limited Renin inhibitors
US9271962B2 (en) * 2008-03-17 2016-03-01 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
BR122013027950A2 (pt) 2008-12-24 2019-12-10 BIAL PORTELA & Cª S A compostos farmacêuticos
KR101297652B1 (ko) * 2010-11-25 2013-08-19 한국과학기술연구원 항암활성을 지닌 카르보아졸계 화합물
CN104080783A (zh) * 2012-01-25 2014-10-01 株式会社益力多本社 吡咯化合物
SG11201408004SA (en) 2012-06-04 2015-01-29 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
SG11201502493XA (en) 2012-10-10 2015-04-29 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
JP2016510810A (ja) 2013-03-12 2016-04-11 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体
AU2014358766B2 (en) 2013-12-04 2019-01-17 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194986T3 (es) * 1995-04-07 2003-12-01 Schering Corp Compuestos de carbonil-piperazinilo y piperidinilo que inhiben la farnesil-protein-transferasa.
US5880128A (en) * 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
DE10035928A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
DE10035927A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
DE10035908A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
FR2815032B1 (fr) * 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
WO2004002965A1 (de) * 2002-06-29 2004-01-08 Zentaris Gmbh Aryl- und heteroarylcarbonylpiperazine und deren verwendung zur behandlung gutartiger und bösartiger tumorerkrankungen
AU2003287965A1 (en) * 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
GB0228417D0 (en) * 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds

Also Published As

Publication number Publication date
CA2528093A1 (fr) 2004-12-16
UY28350A1 (es) 2004-12-31
HK1093339A1 (en) 2007-03-02
EP1641765A1 (fr) 2006-04-05
TW200510344A (en) 2005-03-16
PA8604401A1 (es) 2004-12-16
WO2004108685A1 (fr) 2004-12-16
US20050014765A1 (en) 2005-01-20
CL2004001359A1 (es) 2005-05-06
AU2004245269A1 (en) 2004-12-16
BRPI0411001A (pt) 2006-07-04
JP4805813B2 (ja) 2011-11-02
PE20050226A1 (es) 2005-05-18
IL172222A0 (en) 2011-08-01
JP2006526596A (ja) 2006-11-24
MXPA05012929A (es) 2006-02-28
KR20060006850A (ko) 2006-01-19

Similar Documents

Publication Publication Date Title
AR044586A1 (es) Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion
CY1124837T1 (el) Ενωσεις βενζο[β]θειοφαινιου ως αγωνιστες sting
MD3405471T2 (ro) Noi derivați de amoniu, procedeu pentru prepararea acestora și compoziții farmaceutice care îi conțin
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
MD3313817T2 (ro) Derivați biciclici, un procedeu pentru prepararea lor și compozițiile farmaceutice care îi conțin
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
MD3313850T2 (ro) Noi derivaţi de aminoacizi, procedeu pentru prepararea acestora şi compoziţii farmaceutice care îi conţin
TW200738607A (en) Sulfonamide derivatives, preparation thereof and therapeutic use thereof
AR059314A1 (es) Derivados de las benzamidas y heteroarenos
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AR045462A1 (es) DERIVADOS DE INDOLES SUSTITUIDOS eTILES COMO COMPUESTOS FARMACEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
UY29047A1 (es) Derivados de sulfonamidas, su preparación y su aplicación en terapéutica
PE20091005A1 (es) N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
CR20150056A (es) Derivados de azaindol
GEP20207128B (en) Aminothiazole derivatives useful as antiviral agents
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
EA201001087A1 (ru) Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos
PH12020500408A1 (en) Cycloolefin substituted heteroaromatic compounds and their use
EA200501530A1 (ru) Новые соединения бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат
CY1113733T1 (el) Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων
CY1108584T1 (el) Παραγωγα 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline ως φαρμακα για τη θεραπεια της στειροτητας
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal